Top

Journal of Experimental & Clinical Cancer Research

Published in:

Open Access 01-12-2024 | Thrombocytopenia | Research

The localization, origin, and impact of platelets in the tumor microenvironment are tumor type-dependent

Authors: Ophélie Le Chapelain, Soumaya Jadoui, Angèle Gros, Samir Barbaria, Keltouma Benmeziane, Véronique Ollivier, Sébastien Dupont, Mialitiana Solo Nomenjanahary, Sabrina Mavouna, Jasmina Rogozarski, Marie-Anne Mawhin, Giuseppina Caligiuri, Sandrine Delbosc, Françoise Porteu, Bernhard Nieswandt, Pierre H Mangin, Yacine Boulaftali, Benoit Ho-Tin-Noé

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2024

Abstract

Background

How platelets interact with and influence the tumor microenvironment (TME) remains poorly characterized.

Methods

We compared the presence and participation of platelets in the TME of two tumors characterized by highly different TME, PyMT AT-3 mammary tumors and B16F1 melanoma.

Results

We show that whereas firmly adherent platelets continuously line tumor vessels of both AT-3 and B16F1 tumors, abundant extravascular stromal clusters of platelets from thrombopoietin-independent origin were present only in AT-3 mammary tumors. We further show that platelets influence the angiogenic and inflammatory profiles of AT-3 and B16F1 tumors, though with very different outcomes according to tumor type. Whereas thrombocytopenia increased bleeding in both tumor types, it further caused severe endothelial degeneration associated with massive vascular leakage, tumor swelling, and increased infiltration of cytotoxic cells, only in AT-3 tumors.

Conclusions

These results indicate that while platelets are integral components of solid tumors, their localization and origin in the TME, as well as their impact on its shaping, are tumor type-dependent.

Available only for authorised users

Gasic GJ, Gasic TB, Stewart CC. Antimetastatic effects associated with platelet reduction. Proc Natl Acad Sci U S A. 1968;61:46.ADSPubMedPubMedCentralCrossRef

Labelle M, Begum S, Hynes RO. Direct signaling between platelets and Cancer cells induces an epithelial-mesenchymal-like Transition and promotes metastasis. Cancer Cell. 2011;20:576–90.PubMedPubMedCentralCrossRef

Nieswandt B, Hafner M, Echtenacher B, Männel DN. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res. 1999;59:1295–300.PubMed

Kim YJ, Borsig L, Varki NM, Varki A. P-selectin deficiency attenuates tumor growth and metastasis. Proc Natl Acad Sci U S A. 1998;95:9325–30.ADSPubMedPubMedCentralCrossRef

Jain S, Zuka M, Liu J, Russell S, Dent J, Guerrero JA, et al. Platelet glycoprotein Ibα supports experimental lung metastasis. Proc Natl Acad Sci U S A. 2007;104:9024–8.ADSPubMedPubMedCentralCrossRef

Jain S, Russell S, Ware J. Platelet glycoprotein VI facilitates experimental lung metastasis in syngenic mouse models. J Thromb Haemost. 2009;7:1713–7.PubMedCrossRef

Mezouar S, Darbousset R, Dignat-George F, Panicot-Dubois L, Dubois C. Inhibition of platelet activation prevents the P-selectin and integrin-dependent accumulation of cancer cell microparticles and reduces tumor growth and metastasis in vivo. Int J Cancer. 2015;136:462–75.PubMedCrossRef

Stone RL, Nick AM, McNeish IA, Balkwill F, Han HD, Bottsford-Miller J, et al. Paraneoplastic thrombocytosis in Ovarian Cancer. N Engl J Med. 2012;366:610–8.PubMedPubMedCentralCrossRef

Bottsford-Miller J, Choi HJ, Dalton HJ, Stone RL, Cho MS, Haemmerle M, et al. Differential platelet levels affect response to taxane-based therapy in ovarian cancer. Clin Cancer Res. 2015;21:602–10.PubMedCrossRef

10.

Plantureux L, Mege D, Crescence L, Carminita E, Robert S, Cointe S, et al. The interaction of platelets with colorectal cancer cells inhibits tumor growth but promotes metastasis. Cancer Res. 2020;80:291–303.PubMedCrossRef

11.

Volz J, Mammadova-Bach E, Gil-Pulido J, Nandigama R, Remer K, Sorokin L, et al. Inhibition of platelet GPVI induces intratumor hemorrhage and increases efficacy of chemotherapy in mice. Blood. 2019;133:2696–706.PubMedCrossRef

12.

Cho MS, Bottsford-Miller J, Vasquez HG, Stone R, Zand B, Kroll MH, et al. Platelets increase the proliferation of ovarian cancer cells. Blood. 2012;120:4869–72.PubMedPubMedCentralCrossRef

13.

Michael Jv, Wurtzel JGT, Mao GF, Rao AK, Kolpakov MA, Sabri A, et al. Platelet microparticles infiltrating solid tumors transfer miRNAs that suppress tumor growth. Blood. 2017;130:567–80.PubMedPubMedCentralCrossRef

14.

Egan K, Crowley D, Smyth P, O’Toole S, Spillane C, Martin C et al. Platelet adhesion and Degranulation Induce Pro-survival and Pro-angiogenic Signalling in Ovarian Cancer cells. PLoS ONE. 2011;6.

15.

Ibele GM, Kay NE, Johnson GJ, Jacob HS. Human platelets exert cytotoxic effects on tumor cells. Blood. 1985;65:1252–5.PubMedCrossRef

16.

Kisucka J, Butterfield CE, Duda DG, Eichenberger SC, Saffaripour S, Ware J, et al. Platelets and platelet adhesion support angiogenesis while preventing excessive hemorrhage. Proc Natl Acad Sci U S A. 2006;103:855–60.ADSPubMedPubMedCentralCrossRef

17.

Zhang Y, Cedervall J, Hamidi A, Herre M, Viitaniemi K, D’Amico G, et al. Platelet-specific PDGFB ablation impairs Tumor Vessel Integrity and promotes metastasis. Cancer Res. 2020;80:3345–58.PubMedCrossRef

18.

Ho-Tin-Noé B, Goerge T, Cifuni SM, Duerschmied D, Wagner DD. Platelet granule secretion continuously prevents intratumor hemorrhage. Cancer Res. 2008;68:6851–8.PubMedPubMedCentralCrossRef

19.

Ho-Tin-Noé B, Carbo C, Demers M, Cifuni SM, Goerge T, Wagner DD. Innate Immune cells induce hemorrhage in tumors during Thrombocytopenia. Am J Pathol. 2009;175:1699–708.PubMedPubMedCentralCrossRef

20.

Pavlović N, Kopsida M, Gerwins P, Heindryckx F. Activated platelets contribute to the progression of hepatocellular carcinoma by altering the tumor environment. Life Sci. 2021;277:119612.PubMedCrossRef

21.

Hinterleitner C, Strähle J, Malenke E, Hinterleitner M, Henning M, Seehawer M et al. Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancer. Nat Commun. 2021;12.

22.

Gurney AL, Carver-Moore K, De Sauvage FJ, Moore MW. Thrombocytopenia in c-mpl-deficient mice. Science. 1994;265:1445–7.ADSPubMedCrossRef

23.

Lockyer S, Okuyama K, Begum S, Le S, Sun B, Watanabe T, et al. GPVI-deficient mice lack collagen responses and are protected against experimentally induced pulmonary thromboembolism. Thromb Res. 2006;118:371–80.PubMedCrossRef

24.

Fidler IJ. Biological behavior of malignant melanoma cells correlated to their survival in vivo. Cancer Res. 1975;35:218–24.PubMed

25.

Stewart TJ, Abrams SI. Altered Immune function during long-term host-tumor interactions can be modulated to Retard Autochthonous neoplastic growth. J Immunol. 2007;179:2851–9.PubMedCrossRef

26.

Guy CT, Cardiff RD, Muller WJ. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol. 1992;12:954–61.PubMedPubMedCentral

27.

Lin EY, Jones JG, Li P, Zhu L, Whitney KD, Muller WJ, et al. Progression to Malignancy in the Polyoma Middle T Oncoprotein mouse breast Cancer Model provides a Reliable Model for Human diseases. Am J Pathol. 2003;163:2113–26.PubMedPubMedCentralCrossRef

28.

Pfefferle AD, Herschkowitz JI, Usary J, Harrell JC, Spike BT, Adams JR, et al. Transcriptomic classification of genetically engineered mouse models of breast cancer identifies human subtype counterparts. Genome Biol. 2013;14:1–16.CrossRef

29.

Attalla S, Taifour T, Bui T, Muller W. Insights from transgenic mouse models of PyMT-induced breast cancer: recapitulating human breast cancer progression in vivo. Oncogene. 2021;40:475–91.PubMedCrossRef

30.

Leunig M, Yuan F, Menger MD, Boucher Y, Goetz AE, Messmer K, et al. Angiogenesis, Microvascular Architecture, Microhemodynamics, and interstitial fluid pressure during early growth of human adenocarcinoma LS174T in SCID mice. Cancer Res. 1992;52:6553–60.PubMed

31.

Lockyer S, Okuyama K, Begum S, Le S, Sun B, Watanabe T, et al. Single platelets seal neutrophil-induced vascular breaches via GPVI during immune-complex-mediated inflammation in mice. Blood. 2015;126:1017–26.CrossRef

32.

Wendel M, Galani IE, Suri-Payer E, Cerwenka A. Natural killer cell accumulation in tumors is dependent on IFN-gamma and CXCR3 ligands. Cancer Res. 2008;68:8437–45.PubMedCrossRef

33.

Alexander WS, Roberts AW, Nicola NA, Li R, Metcalf D. Deficiencies in Progenitor cells of multiple hematopoietic lineages and defective megakaryocytopoiesis in mice lacking the Thrombopoietin receptor c-Mpl. Blood. 1996;87:2162–70.PubMedCrossRef

34.

Morowski M, Vögtle T, Kraft P, Kleinschnitz C, Stoll G, Nieswandt B. Only severe thrombocytopenia results in bleeding and defective thrombus formation in mice. Blood. 2013;121:4938–47.PubMedCrossRef

35.

Goerge T, Ho-Tin-Noe B, Carbo C, Benarafa C, Remold-O’Donnell E, Zhao BQ, et al. Inflammation induces hemorrhage in thrombocytopenia. Blood. 2008;111:4958–64.PubMedPubMedCentralCrossRef

36.

Boulaftali Y, Hess PR, Getz TM, Cholka A, Stolla M, Mackman N, et al. Platelet ITAM signaling is critical for vascular integrity in inflammation. J Clin Invest. 2013;123:908–16.PubMedPubMedCentral

37.

Rayes J, Jadoui S, Lax S, Gros A, Wichaiyo S, Ollivier V, et al. The contribution of platelet glycoprotein receptors to inflammatory bleeding prevention is stimulus and organ dependent. Haematologica. 2018;103:e256–8.PubMedPubMedCentralCrossRef

38.

Kaiser R, Escaig R, Kranich J, Hoffknecht ML, Anjum A, Polewka V, et al. Procoagulant platelet sentinels prevent inflammatory bleeding through GPIIBIIIA and GPVI. Blood. 2022;140:121–39.PubMedPubMedCentralCrossRef

39.

Currie SM, Stegmeyer RI, Mildner K, Breitsprecher L, Zeuschner D, Psathaki OE, et al. Confocal Real-Time Analysis of Cutaneous Platelet Recruitment during Immune complex–mediated inflammation. J Invest Dermatology. 2022;142:2724–e27323.CrossRef

40.

Cullen SP, Brunet M, Martin SJ. Granzymes in cancer and immunity. Cell Death Differ. 2010;17:616–23.PubMedCrossRef

41.

Hsu J, Hodgins JJ, Marathe M, Nicolai CJ, Bourgeois-Daigneault MC, Trevino TN, et al. Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade. J Clin Invest. 2018;128:4654–68.PubMedPubMedCentralCrossRef

42.

Juneja VR, McGuire KA, Manguso RT, LaFleur MW, Collins N, Nicholas Haining W, et al. PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity. J Exp Med. 2017;214:895–904.PubMedPubMedCentralCrossRef

43.

Schlesinger M. Role of platelets and platelet receptors in cancer metastasis. J Hematol Oncol. 2018;11.

44.

Le Chapelain O, Ho-Tin-noé B. Intratumoral platelets: harmful or incidental bystanders of the Tumor Microenvironment? Cancers (Basel). 2022;14:2192.PubMedCrossRef

45.

Manegold PC, Hutter J, Pahernik SA, Messmer K, Dellian M. Platelet-endothelial interaction in tumor angiogenesis and microcirculation. Blood. 2003;101:1970–6.PubMedCrossRef

46.

Guo Y, Cui W, Pei Y, Xu D. Platelets promote invasion and induce epithelial to mesenchymal transition in ovarian cancer cells by TGF-β signaling pathway. Gynecol Oncol. 2019;153:639–50.PubMedCrossRef

47.

Zhang Y, Manouchehri Doulabi E, Herre M, Cedervall J, Qiao Q, Miao Z, et al. Platelet-derived PDGFB promotes recruitment of Cancer-Associated fibroblasts, deposition of extracellular matrix and Tgfβ signaling in the Tumor Microenvironment. Cancers (Basel). 2022;14:1947.PubMedPubMedCentralCrossRef

48.

Ho-Tin-Noé B, Boulaftali Y, Camerer E. Platelets and vascular integrity: how platelets prevent bleeding in inflammation. Blood. 2018;131:277–88.PubMedCrossRef

49.

Gupta S, Konradt C, Corken A, Ware J, Nieswandt B, Di Paola J, et al. Hemostasis vs. homeostasis: platelets are essential for preserving vascular barrier function in the absence of injury or inflammation. Proc Natl Acad Sci U S A. 2020;117:24316–25.ADSPubMedPubMedCentralCrossRef

50.

Ho-Tin-Noé B, Le Chapelain O, Camerer E. Platelets maintain vascular barrier function in the absence of injury or inflammation. J Thromb Haemost. 2021;19:1145–8.PubMedCrossRef

51.

Alshehri OM, Hughes CE, Montague S, Watson SK, Frampton J, Bender M, et al. Fibrin activates GPVI in human and mouse platelets. Blood. 2015;126:1601–8.PubMedPubMedCentralCrossRef

52.

Mammadova-Bach E, Ollivier V, Loyau S, Schaff M, Dumont B, Favier R, et al. Platelet glycoprotein VI binds to polymerized fibrin and promotes thrombin generation. Blood. 2015;126:683–91.PubMedCrossRef

53.

Gauer JS, Duval C, Xu RG, Macrae FL, McPherson HR, Tiede C, et al. Fibrin-glycoprotein VI interaction increases platelet procoagulant activity and impacts clot structure. J Thromb Haemost. 2023;21:667–81.PubMedCrossRef

54.

Brockmann MA, Bender B, Plaxina E, Nolte I, Erber R, Lamszus K, et al. Differential effects of tumor-platelet interaction in vitro and in vivo in glioblastoma. J Neurooncol. 2011;105:45–56.PubMedCrossRef

55.

Li R, Ren M, Chen N, Luo M, Deng X, Xia J et al. Presence of intratumoral platelets is associated with tumor vessel structure and metastasis. BMC Cancer. 2014;14.

56.

Haas S, Hansson J, Klimmeck D, Loeffler D, Velten L, Uckelmann H, et al. Inflammation-Induced Emergency Megakaryopoiesis Driven by hematopoietic stem cell-like megakaryocyte progenitors. Cell Stem Cell. 2015;17:422–34.PubMedCrossRef

57.

Nishimura S, Nagasaki M, Kunishima S, Sawaguchi A, Sakata A, Sakaguchi H, et al. IL-1α induces thrombopoiesis through megakaryocyte rupture in response to acute platelet needs. J Cell Biol. 2015;209:453–66.PubMedPubMedCentralCrossRef

58.

Couldwell G, Machlus KR. Modulation of megakaryopoiesis and platelet production during inflammation. Thromb Res. 2019;179:114–20.PubMedCrossRef

59.

Morodomi Y, Kanaji S, Sullivan BM, Zarpellon A, Orje JN, Won E, et al. Inflammatory platelet production stimulated by tyrosyl-tRNA synthetase mimicking viral infection. Proc Natl Acad Sci U S A. 2022;119:e2212659119.PubMedPubMedCentralCrossRef

60.

Matsubara Y, Murata M, Ikeda Y. Culture of megakaryocytes and platelets from subcutaneous adipose tissue and a preadipocyte cell line. Methods Mol Biol. 2012;788:249–58.PubMedCrossRef

61.

Zhang J, Zhou S, Zhou Y, Feng F, Wang Q, Zhu X, et al. Adipose-derived mesenchymal stem cells (ADSCs) with the potential to ameliorate platelet recovery, enhance megakaryopoiesis, and inhibit apoptosis of bone marrow cells in a mouse model of Radiation-Induced Thrombocytopenia. Cell Transpl. 2016;25:261–73.CrossRef

62.

Tozawa K, Ono-Uruga Y, Yazawa M, Mori T, Murata M, Okamoto S, et al. Megakaryocytes and platelets from a novel human adipose tissue-derived mesenchymal stem cell line. Blood. 2019;133:633–43.PubMedPubMedCentralCrossRef

63.

Gros A, Ollivier V, Ho-Tin-Noé B. Platelets in inflammation: regulation of leukocyte activities and vascular repair. Front Immunol. 2015;5:678.PubMedPubMedCentralCrossRef

64.

Riesenberg BP, Ansa-Addo EA, Gutierrez J, Timmers CD, Liu B, Li Z. Cutting Edge: Targeting thrombocytes to rewire anticancer immunity in the Tumor Microenvironment and Potentiate Efficacy of PD-1 blockade. J Immunol. 2019;203:1105–10.PubMedCrossRef

65.

Zaslavsky AB, Adams MP, Cao X, Maj T, Choi JE, Stangl-Kremser J, et al. Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors. Sci Rep 2020. 2020;10:1.

66.

Darga EP, Dolce EM, Fang F, Kidwell KM, Gersch CL, Kregel S et al. PD-L1 expression on circulating tumor cells and platelets in patients with metastatic breast cancer. PLoS ONE. 2021;16.

Title: The localization, origin, and impact of platelets in the tumor microenvironment are tumor type-dependent
Authors: Ophélie Le Chapelain
Soumaya Jadoui
Angèle Gros
Samir Barbaria
Keltouma Benmeziane
Véronique Ollivier
Sébastien Dupont
Mialitiana Solo Nomenjanahary
Sabrina Mavouna
Jasmina Rogozarski
Marie-Anne Mawhin
Giuseppina Caligiuri
Sandrine Delbosc
Françoise Porteu
Bernhard Nieswandt
Pierre H Mangin
Yacine Boulaftali
Benoit Ho-Tin-Noé
Publication date: 01-12-2024
Publisher: BioMed Central
Keywords: Thrombocytopenia
Solid Tumor
Published in: Journal of Experimental & Clinical Cancer Research / Issue 1/2024
Electronic ISSN: 1756-9966
DOI: https://doi.org/10.1186/s13046-024-03001-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2024

S100A9+CD14+ monocytes contribute to anti-PD-1 immunotherapy resistance in advanced hepatocellular carcinoma by attenuating T cell-mediated antitumor function

Pan-cancer analysis implicates novel insights of lactate metabolism into immunotherapy response prediction and survival prognostication

A novel PDPN antagonist peptide CY12-RP2 inhibits melanoma growth via Wnt/β-catenin and modulates the immune cells

Combined IL6 and CCR2 blockade potentiates antitumor activity of NK cells in HPV-negative head and neck cancer

HSPA4 upregulation induces immune evasion via ALKBH5/CD58 axis in gastric cancer

Unraveling the complexity of STAT3 in cancer: molecular understanding and drug discovery

Keynote webinar | Spotlight on antibody–drug conjugates in cancer